Highlights and recent developments in allergic diseases in EAACI journals (2019)
- PDF / 892,546 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 69 Downloads / 166 Views
Clinical and Translational Allergy Open Access
REVIEW
Highlights and recent developments in allergic diseases in EAACI journals (2019) J. Bousquet1,9* , C. E. Grattan3, C. A. Akdis2, P. A. Eigenmann4, K. Hoffmann‑Sommergruber5, I. Agache6 and M. Jutel7,8
Abstract The European Academy of Allergy and Clinical Immunology (EAACI) owns three journals: Allergy, Pediatric Allergy and Immunology and Clinical and Translational Allergy. One of the major goals of EAACI is to support health promo‑ tion in which prevention of allergy and asthma plays a critical role and to disseminate the knowledge of allergy to all stakeholders including the EAACI junior members. There was substantial progress in 2019 in the identification of basic mechanisms of allergic and respiratory disease and the translation of these mechanisms into clinics. Better under‑ standing of molecular and cellular mechanisms, efforts for the development of biomarkers for disease prediction, novel prevention and intervention studies, elucidation of mechanisms of multimorbidities, entrance of new drugs in the clinics as well as recently completed phase three clinical studies and publication of a large number of allergen immunotherapy studies and meta-analyses have been the highlights of the last year. Keywords: Asthma, Rhinitis, Atopic dermatitis, Urticaria, Anaphylaxis, Food allergy, Angioedema, Allergens, Immunotherapy, EAACI Introduction The European Academy of Allergy and Clinical Immunology (EAACI) has three official journals: Allergy, Pediatric Allergy and Immunology and Clinical and Translational Allergy. One of the major goals of EAACI is to support health promotion in which prevention and control of allergy plays a critical role and to disseminate the knowledge of allergy to all stakeholders including the EAACI junior members. The EAACI journals have reported on all fields of allergy and related diseases in 2018 and 2019 [1–4]. This paper summarises some of the achievements of 2019. Several EAACI Position Papers have been published in 2019 [5–15].
*Correspondence: [email protected] 9 CHRU Arnaud de Villeneuve, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France Full list of author information is available at the end of the article
Allergic diseases Der p 24 is a major Dermatophagoides pteronyssinus (HDM) allergen with strong IgE binding activity via an immunodominant IgE epitope in the N-terminal 32-residue region, which triggers IgE production in vivo [16]. The identified Der p 24 epitope may support HDM allergy diagnosis and treatment. Major mite allergens from European standardized commercial extracts for in vivo diagnosis were evaluated [17]. Certain natural Dermatophagoides pteronyssinus and Blomia tropicalis extracts lack important allergens showing a considerable variability in composition and content. There is a need to improve the quality and consistency of these extracts to achieve a more precise diagnosis and treatment of house dust mite allergy. Skin prick tests (SPTs) are essential for the diagnosis of IgE-media
Data Loading...
